Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type (1 selected)

Type

Guidance programme

HealthTech approach

HealthTech approach

Area of interest

Showing 651 to 700 of 2047

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and overHST20
Liposuction for chronic lymphoedemaHTG622
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA787
Elosulfase alfa for treating mucopolysaccharidosis type 4AHST19
Intramedullary distraction for upper limb lengtheningHTG621
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adultsNG215
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Stroke and transient ischaemic attack in over 16s: diagnosis and initial managementNG128
UroShield for preventing catheter-associated urinary tract infectionsHTG620
Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment)HTG619
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)TA782
Liposuction for chronic lipoedemaHTG618
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Integrated health and social care for people experiencing homelessnessNG214
Otitis media (acute): antimicrobial prescribingNG91
Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitisHTG617
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA777
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA776
Prontosan for treating acute and chronic woundsHTG616
3C Patch for treating diabetic foot ulcersHTG615
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomachHTG612
Intramedullary distraction for lower limb lengtheningHTG613
Endoscopic balloon dilation for subglottic or tracheal stenosisHTG614
Mental wellbeing at workNG212
PredictSURE IBD and IBDX to guide treatment of Crohn's diseaseHTG610
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodulesHTG611
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Odevixibat for treating progressive familial intrahepatic cholestasisHST17
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Stereotactic radiosurgery for trigeminal neuralgiaHTG608
Microwave ablation for primary or metastatic cancer in the lungHTG609
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Ponesimod for treating relapsing–remitting multiple sclerosisTA767
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDsTA768
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive careHTG607
Glaucoma: diagnosis and managementNG81

Results per page

  1. 10
  2. 25
  3. 50
  4. All